Method for treatment and prophylaxis of gastrointestinal infection disease in piglets under condition of industrial swine breeding

FIELD: veterinary science.

SUBSTANCE: invention involves the combined use of antibacterial preparations and immunomodulator. Method involves complex of single and double RNA sodium salts from killer yeast Saccharomyces cerevisiae as an immunomodulator and synthetic polymer-carrier taken in the dose 0.3-0.4 mg/kg. Immunomodulator is administrated in animals in a single dose before onset of critical period, i. e. in 15-20 days of piglets growing. Method provides stimulation of factors of cellular and humoral immunity of animals without adverse reactions and complication due to selection of optimal dose of immunomodulator and its prolonged effect.

EFFECT: improved method for treatment and prophylaxis.

3 cl, 4 tbl, 3 ex

 

The invention relates to veterinary science, particularly to a method for the treatment and prevention of gastrointestinal infectious diseases of animals in intensive pig production.

There is a method of treatment of gastrointestinal diseases of pigs with antibiotics and immunomodulatory drugs, including the use of antibiotic (neomycin sulfate) and antihistamines serum with a titer of antibodies to histamine 1:256 in the dose of 1.5-2.0 ml on the head once a day, three times with an interval of 3-4 days [RF Patent №2185855, class a 61 K 39/395, publ. BI No. 21 2002].

The disadvantage of this method is its high cost and complexity of making the antihistamine serum, because the drug is produced by hyperimmunization horses gistoglobulina according to a certain scheme.

In addition, the spectrum of action of neomycin sulfate is very limited. In particular, it has no effect on Mycoplasma, and hyperimmune serum has a limited effect on humoral immunity (only at the expense of globulins).

The closest solution is used as a prototype, is a method of treatment of gastrointestinal diseases of pigs with the use of antimicrobial agent in formazin (0.2 ml/kg of 1 per day) in combination with boosting means which are used, in the first case, thevitamin citrate and blood horses; in the second case - Trivium the n and rodest 1%5 ml [Polozek O.N. The effect of Immunostimulants on humoral factors of natural resistance of piglets at gastroenteritis// Actual. Probl. pig Russia. - Pic. Persianovskaya, 1999, - P.85-86].

The disadvantage of this method is the high cost and complexity of making nitrate horse blood.

An object of the invention is to develop effective treatment and prevention of gastrointestinal disease of pigs in industrial complexes.

The problem is solved in that in the known method of treatment and prevention of gastrointestinal disease of pigs, including the combined use of antibiotics and immunomodulator, characterized in that as an immunomodulator use complex sodium salts of single - and double-stranded RNA killer yeast Saccharomyces cerevisiae and a synthetic polymer carrier at a dose of 0.3-0.4 mg/kg

The invention also lies in the fact that the immunomodulator is administered to the animals once.

The invention also lies in the fact that the combined use of antibiotics and immunomodulator conduct in anticipation of a critical period of 15-20 days of growing pigs.

To illustrate the invention the following examples of its practical application.

Example 1. To determine the optimal doses of the complex of the sodium salts of single - and double-stranded RNA killer yeast Saccharomyces cerevisiae and a synthetic polymer carrier (complex A) in industrial pig-breeding complex of JSC "kudryashovsky piggery" made the experiment on 50 pigs at the age of 18 days, live weight 4,5 kg

Pigs on the principle of analogues were divided into 5 groups of 10 animals each. Animals of the first three groups were injected complex And doses 0,05-0,1; 0,3-0,4; 0,5-0,6 mg/kg Pigs fourth group for comparison was introduced previously studied WESTIN at a dose of 0.5 mg/kg of Drugs were injected intramuscularly. The piglets of the fifth group no drugs were injected control.

Prior to the introduction of drugs, and then after 3, 10 days in the blood of piglets was determined phagocytic activity, phagocytic index and phagocytic neutrophil count and the serum total protein and its fractions.

In the analysis of the absorption capacity of neutrophils blood marked increase in phagocytic activity of neutrophils in animals of the second and fourth groups. Animals of the second group after administration of compound a at a dose of 0.3 mg/kg phagocytic activity of neutrophils was significantly increased from 52±a 4.83 70±1,84%, P<0.05 on day 3.

In piglets fourth group phagocytic activity of neutrophils was significantly increased on day 3 after the introduction of the WESTIN to 71±3,50%, P<0,05 and on day 10 had dropped to 66±1,25%, but was higher than the background value, P<0,05. In piglets third group phagocytic activity of neutrophils after drug administration were decreased, and the 10 days was significantly lower than before its introduction (61±1,58%, P<0,05) (table 1).

Table 1
Adsorption capacity of neutrophils in the blood of pigs after administration of preparations of the complex And (in different doses) and WESTIN (at a dose of 0.5 mg/kg)
Phagocytic activity, %Phagocytic index, M.L./WellPhagocytic number, M.L./At
The first group
Before the introduction of67±4,336±0,718±0,62
On day 368±2,086±0,518±0,55
On day 1061±3,565±0,588±0,64
The second group
Before the introduction of52±a 4.834±0,587±0,99
On day 370±1,84*5±0,617±0,74
On day 1053±3,563±0,64**6±0,86
The third group
Before the introduction of73±or 4.318±2,169±2,03
On day 371±1,586±0,48
On day 1061±1,58 *4±0,407±0,51
The fourth group
Before the introduction of55±1,534±0,136±0,42
On day 371±3,50 *5±0,56*8±0,52
On day 1066±1,25*5±0,44*8±0,79
The fifth group
Before the introduction of63±3,437±0,928±1,11
On day 365±1,556±0,577±0,88
On day 1061±2,306±0,307±0,47
Note:

The first group - the complex And 0.05-0.1 mg/kg, the second group - the complex And 0.3-0.4 mg/kg, the third group - the complex And 0.5-0.6 mg/kg, the fourth group - the WESTIN 0.5 mg/kg, the fifth group of the control.

* - P<0,05 in comparison with the background.

** P<0,05 compared to control.

The total protein content in animals after administration of compound a at a dose of 0.3-0.4 mg/kg on day 3 was significantly higher than that in control the data (5,66± 0.16 g%, P<0,05).

The content of gamma globulin was significantly increased compared with the background only in the serum of animals of the second group (0,47±0.06 to 0.74 and±0.09 g%, P<0.05), and in animals of the fourth group its content significantly decreased to 10 days to 0.45±0.03 g%, P<0,05 (table. 2).

Thus, in the result of experiments, it was found that the phagocytic activity of neutrophils in the blood of piglets increased on day 3 after administration of compound a at a dose of 0.3-0.4 mg/kg by 34.6%, and after the introduction WESTIN 29%.

The increase in the number of total protein observed on day 3 after administration of compound a at a dose of 0.3-0.4 mg/kg 6.2%.

A significant increase in the content of gamma globulin in the blood serum of piglets (57,4%) were observed on day 3 after administration of compound a at a dose of 0.3 mg/kg

Therefore, the study immunomodulator complex And tested doses was safe for pigs and did not arouse adverse reactions and complications. Judging by the performance of phagocytosis of blood and increased levels of gamma globulin, complex And entered the pigs at a dose of 0.3-0.4 mg/kg significantly stimulates cellular and humoral factors of immunity of piglets. Optimal immunostimulatory complex dose And should be considered as 0.3-0.4 mg/kg Zh.M.

Example 2. In industrial pig-breeding complex of JSC "Kudryashev the e examined therapeutic efficacy of the combined use of antibacterial drug of tiamutin [maple IVAN, Ilyukhin I.N., Napisana L.A. Foreign veterinary drugs in Russia. The Handbook. M., 1999. - 320 S.] and immunomodulator based on sodium salts of single - and double-stranded RNA killer yeast Saccharomyces cerevisiae and a synthetic polymer carrier [RF Patent №2172631, class a 61 K 31/70, publ. BI No. 24, 2001] in the gastro-intestinal diseases of pigs.

Previously in piglets at weaning plot rearing was defined microbial and viral background. Bacteriological and serological studies have established carrier in piglets Escherichia, Salmonella, pasteurellosis, Escherichia coli, Rota - and coronaviruses.

For experiment picked up 42 piglets at the age of 50 days with symptoms of diarrhea, retarded, live weight of 4.5-5.5 kg each.

Pigs-analogues were divided into 2 groups of 14 animals each.

Animals of the first group has introduced a 10% solution of tiamulin at a dose of 10 mg/kg daily for three consecutive days and immunomodulator based on sodium salts of single - and double-stranded RNA killer yeast Saccharomyces cerevisiae and a synthetic polymer carrier once on the first day of treatment. The piglets of the second group was injected only tiamutin at a dose of 10 mg/kg

Daily for 14 days, have been monitoring the clinical status of piglets. The effectiveness of different schemes for the use of drugs was assessed by the increase in live weight and level sopranos and pigs.

In the first group, after application of tiamulin and immunomodulator fell 1 pig, safety amounted to 92.9%of the average daily weight gain 107±, and 7.7 g, P<0,05.

In the group of animals that were injected only tiamutin, Palo 4 pig, safety and the average daily weight gain were within 71,4% and 64±and 5.8, respectively (table. 3).

Table 3
Therapeutic efficacy of immunomodulator with the simultaneous use of tiamulin for gastro-intestinal diseases of pigs
GroupAt the beginning of the experimentAfter 14 days
Qty goal.the average weight of 1 goal.Qty goal.the average weight of 1 goal.caseAverage daily gain, gsafety, %
goal.%
Tiamutin and immunomodulator14the 4.7136,217,1107±7,7*92,9
Tiamutin (control)144,510of 5.44 28,664±5,871,4
Note: * - P<0.05 compared with the control group

Thus, the best therapeutic effect obtained in the first group from the combined use of tiamulin and single use of the immunomodulator, which fell one pig out of 14, the other recovered. The average daily gain in body weight in this group was 1.7 times higher than in the group where only used antibacterial drug - tiamutin.

Example 3. In the manufacturing experience has studied the effectiveness of the combined use of antibiotic a broad spectrum of lieterally [Kovalev V.F., wolves IB, Violin BV Antibiotics, sulfonylamides and nitrofurans in veterinary medicine. The Handbook. - M., 1988. - 223 C.] and immunomodulator based on sodium salts of single - and double-stranded RNA killer yeast Saccharomyces cerevisiae and a synthetic polymer carrier for the prevention of gastrointestinal diseases of pigs.

It was established that in industrial pig production is most often outbreaks of gastrointestinal diseases occur in certain periods of the growing "critical periods". Their mark in weaning piglets from sows and translated into self-feeding, when translating from one room to another with the formation of new groups p is reset. These periods are stressful for animals, stress is reduced nonspecific resistance of the organism of pigs. Against this background, conditionally pathogenic microflora becomes pathogenic properties and causes primarily gastrointestinal disease of pigs. Increased mortality. This method of prevention allows on the one hand to increase the body's resistance (immunomodulator), on the other hand to suppress the development of pathogenic microflora (antibacterial drug).

For the experiment took 235 pigs equivalents at the age of 18 days, live weight 4.3 kg each, without clinical signs of gastrointestinal disease.

The piglets of the first group of 18-day life ("threshold" critical period) has introduced lieterally at a dose of 2 ml/goal and at the same time immunomodulator based on sodium salts of single - and double-stranded RNA killer yeast Saccharomyces cerevisiae and a synthetic polymer carrier at a dose of 0.3-0.4 mg/kg Pigs of the second group was injected only lieterally at a dose of 2 ml/kg once (control 1). Animals of the third group no drugs were injected (control 2).

For pigs daily for 24 days, conducted clinical observations. The effectiveness of different regimens of chemotherapy were evaluated for productivity and safety of pigs.

In the first group, after the introduction of the IMM is demodulator and levocetrizine within 24 days Palo and have killed 3 little pigs, the safety of 94.3%, average daily weight gain - 145±10,5 g P<0,05.

In the second group, after the introduction of levocetrizine Palo and forcibly killed 11 piglets, safety amounted to 87.1%, and the average daily weight gain - 102±9,5,

In the control group of piglets fell and forced killed 17 goals. Safety was 82.5%, and the average daily weight gain 117±7,4, (PL. 4).

Table 4
Prophylactic efficacy of pigs immunomodulator with the simultaneous use of levocetrizine
GroupAt the beginning of the experimentAfter 24 days
Qty goal.the average weight of 1 goal.Qty goal.the average weight of 1 goal.cases in/slaughterAverage daily gain, gsafety, %
goal.%
Immunomodulator and lieterally534,5507,935,6145±10,5*94,3
Control 1 (lion is tetrasulfide) 854,2746,61112,9102±9,587,1
Control 2 (intact)974,3807,117of 17.5117±7,482,5
Note: * - P<0.05 compared with the control group

Thus, in animals, which were simultaneously applied immunomodulator, lieterally, average daily weight gain was 42% and 24% higher than in piglets second and third groups. The best preservation was among piglets, which were invoked lieterally and immunomodulator - 94,3%.

From this it follows that immunomodulator, stimulating factors of cellular and humoral immunity of piglets, increases therapeutic efficacy of antibacterial drug tiamutin and therapeutic effectiveness levocetrizine.

Thus, our proposed method can effectively increase the safety of young pigs and increase average daily gain.

1. Method for the treatment and prevention of gastrointestinal disease of pigs, including the combined use of antibiotics and immunomodulator, characterized in that the quality is TBE immunomodulator use complex sodium salts of single - and double-stranded RNA killer yeast Saccharomyces cerevisiae and a synthetic polymer carrier at a dose of 0.3-0.4 mg/kg

2. The method according to claim 1, wherein the immunomodulator is administered to the animals once.

3. The method according to claim 1, characterized in that the combined use of antibiotics and immunomodulator conduct in anticipation of a critical period of 15-20 days of growing pigs.



 

Same patents:

FIELD: medicine, pediatrics, pulmonology, allergology.

SUBSTANCE: method involves administration of viferon by rectal way. Viferon-1 is dosed to children of age 3-6 years (150000 IU in one suppository), and viferon-2 is dosed to children of age 7-14 years (500000 IU in one suppository) every day, twice per a day, for 10 days and then for 4 weeks in every other day. Proposed invention promotes to decrease numbers of bronchial asthma exacerbation, diminishing degree of bronchial asthma severe attack, decreasing frequency of bronchial asthma, increasing period of bronchial asthma remission due to activation of the interferon system. Invention can be used in treatment of bronchial asthma in children suffering from ARVI often and/or for a long time.

EFFECT: enhanced effectiveness of treatment.

6 tbl, 3 ex

FIELD: pharmaceutical industry, in particular immunomodulating agents and production of pharmaceutical compositions containing the same.

SUBSTANCE: claimed immunomodulating agent represents complex of monosulfated cucumariosides with sterol in molar ratio cucumariosides/sterol of 1:2. Said complex is obtained by addition of sterol solution to extract from Cucumaria japonica, or extract of wastewater from Cucumaria japonica processing, or cucumarioside solution. As sterol solution cholesterol or sitosterol. Pharmaceutical composition having immunomodulating activity contains abovementioned agent and filler in specific component ratio.

EFFECT: non-toxic pharmaceutical composition useful as tumor inhibitory agent.

4 cl, 11 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: one should carry out antibacterial and infusion therapy. Moreover, additionally, after compensating the volume of circulating blood during infusion therapy one should intravenously inject 30 thousand IU antigangrenous polyvalent equine serum by drops per 200 ml isotonic NaCl solution: the first 1 ml solution should be injected for 5 min, the rest volume - for 1-1.5 h. The innovation suggested enables to optimize immunocorrecting therapy without sensitizing patient's body.

EFFECT: higher efficiency of therapy.

3 ex, 1 tbl

FIELD: pharmaceutical industry, in particular drug containing human recombinant alpha-2 interferon.

SUBSTANCE: claimed prolonged solution contains human recombinant alpha-2 interferon, citric acid, boric acid, sodium tetraborate, unithiol, human serum albumin, sodium chloride, sodium carboxymethylcellulose and purified water. Preparation of present invention has wide spectrum of therapeutic application.

EFFECT: drug of high specific antiviral and antimicrobial activity without side effects.

1 tbl, 3 ex

FIELD: medicine, pediatrics.

SUBSTANCE: in small children at syndrome of increased thymus gland degree 1-3 one should prescribe prednisolone and eubiotics simultaneously, and at degree 2-3 it is necessary to prescribe immunomodulating agents, additionally. The innovation provides increased anti-infectious immunity and inspecific body resistance due to efficient correction of hormonal state in this group of children.

EFFECT: higher efficiency of prophylaxis.

2 cl, 1 ex

FIELD: veterinary obstetrics.

SUBSTANCE: the method deals with subcutaneous injection of bioglobin (placenta denaturated suspended - PDS) at the quantity of 20 mg/animal/d not earlier that 10 d before calving. The innovation enables to increase quality in preventing the onset of functional dyspepsia in newborn calves and level of total body resistance.

EFFECT: higher efficiency.

20 dwg, 1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vestibular and auditory disorders, trigeminal nerve's neuralgia and peripheral paresis of facial nerve of herpetic etiology. The method deals with introduction of an antiherpetic preparation followed by immunomodelling therapy with the use of polyoxidonium. Moreover, after treating with antiherpetic preparation before introducing polyoxidonium it is necessary to conduct additional successive therapy: with preparations of trophic action as milgamma or neuromultivit at simultaneous introduction of antioxidant, then comes intratissue injection of cerebrolysine being behind the top of mastoid process.

EFFECT: the innovation enables to decrease the quantity of relapses due to stopping the development of herpes simplex virus, restore conductivity along nervous fiber and improve endoneural circulation.

3 cl, 3 ex

Medicinal agent // 2268037

FIELD: medicine, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to using 4-chloro-2-methylphenoxyacetic acid of the formula (I)

and its pharmacologically acceptable sodium, potassium and lithium salts (mixture of these salts, or mixture of salts and 4-chloro-2-methylphenoxyacetic acid) as a medicinal agent possessing immunomodulating, anti-inflammatory and antitumor properties, and antiviral activity also. 4-Chloro-2-methylphenoxyacetic acid and its mixtures with pharmacologically acceptable alkaline metal salts possess high effectiveness and enhanced bioavailability.

EFFECT: valuable medicinal properties of medicinal agent.

9 cl, 13 ex

FIELD: chemistry of peptides, medicine.

SUBSTANCE: invention relates to preparing new peptides possessing immunomodulating, anti-proliferative, anti-tumor and antiviral activity. Invention proposes new peptides comprising up to 30 amino acid residues of the general structural formula: X1-Trp-Gly-Gln-X2 wherein X1 is taken among the following group: -His-Gly-Val-Ser-Gly-, -His-Gly-Gly-Gly-, -His-Val-Gly-Gly-, -His-Gly-Gly-Gly-Gly-, and -Gln-Gly-Gly-Gly-Gly, or absent; X2 is taken among the following group: -His-Gly-Thr-His-Gly, -Gly-Gly-Thr-His-Gly, -Pro-His-Val-Gly-Gly, -Pro-His-Gly-Gly-Gly, -Pro-His-Gly-Gly-Gly-Trp-Gly, -Gly-Gly-Gly-Thr-His-Ser, or absent.

EFFECT: valuable medicinal properties of peptides.

8 cl, 5 tbl, 5 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: method involves administering diacerine influencing DNA synthesis for reducing keratinocytes proliferation without changing their vital activity, inhibiting interleukines IL-1,IL-6 and α-TNF (tumor necrosis factor).

EFFECT: enhanced effectiveness of treatment.

11 cl, 7 dwg, 2 tbl

FIELD: veterinary science.

SUBSTANCE: invention proposes a preparation for treatment and prophylaxis of mastitis in cows at onset of the lactation period and in dry cows that comprises the following components, wt.-%: furacrylin, 0.4-0.6; dioxydin, 0.8-1.2; bee wax, 4-6, and sunflower oil, the balance. The preparation is heated to 38-40°C and administrated in cow mammary gland being in damaged and healthy lobules of udder through a nipple duct by using a syringe in the dose 5 ml. Using the preparation provides enhancing therapeutic and prophylactic effectiveness, decreasing labor intensity in treatment and prophylaxis of mastitis in cows at the lactation period and in dry cows.

EFFECT: enhanced and valuable properties of preparation.

3 tbl, 3 ex

FIELD: organic chemistry, antibiotics, pharmacy.

SUBSTANCE: invention relates to 9a-N-[N'-(phenylsulfonyl)carbamoyl]-derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A that are new semisynthetic macrolide antibiotics relating to class of azalides showing antibacterial effect and describing by the general formula (1):

wherein R1 means hydrogen atom (H), (C1-C4)-alkyl or halogen atom; R means H or cladinosyl radical, and to their pharmaceutically acceptable salts. Also, invention relates to a method for their preparing and a pharmaceutical composition based on thereof.

EFFECT: improved preparing method, valuable medicinal properties of derivatives.

16 cl, 2 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: method involves covering lesion focus with cell containing dialysis solution composed of Dimexid, antibiotic, 0.1% potassium furagin and 25% glucose solution taken in 1:4:3:2 proportion. The cell is fixed on teeth with ligature. Cell wall adjacent to gingiva is covered with semipermeable Cuprofan membrane and the opposite wall with latex rubber. Dialysis is carried out 20 min long twice a day.

EFFECT: enhanced effectiveness of treatment; retained natural protection factors; reduced edema and inflammation manifestations.

Modified chitosan // 2269542

FIELD: organic chemistry of natural compounds, chemical technology, medicine.

SUBSTANCE: invention relates to the group of chitosan-containing compounds. Invention relates to synthesis of modified chitosan of the following structure: wherein n = 150-1400. The modified chitosan possesses the bactericidal activity, in particular, antituberculosis activity.

EFFECT: valuable medicinal properties of modified chitosan.

1 tbl, 1 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with technique of revaccination in adults against diphtheria and tetanus under conditions of Far North. For this purpose one should form a group of people vaccinated more than 10 years ago to vaccinate them in February. The method leads to increased efficiency of vaccination due to decreased duration of vaccination period.

EFFECT: higher efficiency of revaccination.

7 ex

FIELD: medicine, obstetrics.

SUBSTANCE: one should conduct antibacterial therapy 3 mo before planned pregnancy consisting of preparations of tetracyclinic group or macrolides in combination with nystatin and metronidasol to continue it since the first day of menstrual cycle and, also, it is necessary to perform correction of vaginal biocenosis, and about 3-4 wk after therapy carried out for 2 next mo before planned pregnancy starting, also, since the first day of menstrual cycle - metabolic therapy; At the onset of pregnancy one should conduct courses for preventing placental deficiency dealing with introduction of preparations that improve uterine-placental circulation, and preparations that improve rheological properties of blood and vitamin-metabolic therapy or the same preparations, and additionally - introduction of macrolides ad viferon rectally in case of activation of chlamydial infection. The present innovation enables to sanitize uterine cavity, improve uterine-placental circulation, restoration of placental tissue structure that, in its turn favors the birth of healthy generation.

EFFECT: higher efficiency of prophylaxis.

1 cl, 9 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: medicinal formulation possessing the bacteristatic effect consists of a core comprising the following components, wt.-%: clarithromycin, 40.0-80.0; polyvinylpyrrolidone, 3.0-10.0; sodium lauryl sulfate, 2.0-5.0; sodium croscarmelose, 4.0-10.0; aerosil, 0.5-2.0; magnesium stearate, 0.5-2.0, and microcrystalline cellulose, 10.0-31.0. Also, the medicinal formulation consists of envelope comprising the following components, wt.-%: hydroxypropylmethylcellulose, 30.0-70.0; polyethylene glycol, 12.0-22.0; titanium dioxide, 11.0-20.0, hydroxypropylcellulose, 2.0-10.0, dye yellow quinoline, 1.0-4.0, and vanillin, 1.0-4.0. Also, invention describes a method for preparing the medicinal formulation by wet granulation followed by tableting and applying the envelope from an aqueous suspension. Prepared tablets show the necessary mechanical strength, insignificant scattering index by mass (± 3.5%) and dissolving 88-91% for 30 min.

EFFECT: improved and valuable properties of medicinal formulation.

3 cl, 2 tbl

FIELD: medicine, gynecology, surgery.

SUBSTANCE: one should introduce 3.5%-chitosan ascorbate gel into fistulous channel that contains metronidasol at the dosage of 2 mg/ml, at the volume up to 20 ml once/2 d till complete fistula's closing. The present innovation enables to activate reparative processes and fistulous epithelization that favors for closing fistulous channel in earlier terms.

EFFECT: higher efficiency of therapy conducted.

2 ex

FIELD: medicine, surgery.

SUBSTANCE: one should apply a polycompositional film onto donor's wounds after autodermoplasty performed. This film contains the following components in weight proportions: chitosan 78.3-89.4; polyvinyl alcohol 9.8-19.8; antibiotic of aminoglycoside group 0.5-2.0; anesthetic 0.1-0.2. It is perforated at tension coefficient being 1:4. The innovation enables to decrease wound's traumatization, improves prophylaxis of suppuration and increases cosmetic effect even at a single application of the film suggested.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with application of pleuromutilin derivatives, that is valnemulin and thiamulin, for transdermal treatment of bacterial diseases, in particular those induced by Dichelobacter nodosus, Fusobacterium necrophorum, Bacteriodes nodosus and Bacteriodes melamnogenicus, for manufacturing medicinal preparation or as an active ingredient of medicinal preparation of the same indication and corresponding method for transdermal treatment of diseases, for example foot rot. It has been detected the capacity of antibiotics to penetrate skin and enter either plasma or blood at concentrations being efficient against systemic bacterial infections, so, medicinal preparation could be designed in the form of ointment, cream, solution, shampoo, powder and spray.

EFFECT: higher efficiency of application.

9 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves using known quantity of at least one agent hindering from healing when delivering or selecting an agent (the first agent). The agent hindering from healing is used in a quantity showing effectiveness in reducing transdermal movement of the first agent in comparison to movement of the first agent under practically identical conditions with the exception of absence of the mentioned at least one agent hindering from healing. A special-purpose device is used for applying the method and a set of accessories for setting the device.

EFFECT: enhanced effectiveness of treatment.

48 cl, 8 dwg, 3 tbl

Up!